Ifinatamab Deruxtecan — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

11 Recruiting

1 Completed trials

2 Sponsors

17 Countries

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II: 4 Phase I/II: 6

Oversight events:

10 temporary halts 1 urgent safety measure 2 corrective measures across 3 trials

View oversight register →

Indications tested

Small cell lung cancer extensive stage 2 Small cell lung cancer 2 Prostate cancer metastatic 1 Adenocarcinoma gastric 1 Hepatocellular carcinoma 1 Ovarian cancer 1 Squamous cell carcinoma of head and neck 1 Endometrial cancer 1 Colorectal cancer 1 Non-small cell lung cancer stage IV 1 Breast cancer 1 Hormone receptor positive HER2 negative breast cancer 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 8 Daiichi Sankyo Inc. 5

All trials

13 total

A clinical trial of ifinatamab deruxtecan in people under age 18 who have certain types of cancer (MK-9999-01D) Pending

2025-522339-32-00 Phase I/II 7 countries Merck Sharp & Dohme LLC
A clinical trial of ifinatamab deruxtecan in people with advanced esophageal cancer (MK-3475-06F) Recruiting

2026-525213-31-00 Phase II 4 countries Merck Sharp & Dohme LLC
A clinical study of treatments for non-small cell lung cancer (MK-3475-01I) Recruiting

2024-518839-11-00 Phase II 6 countries Merck Sharp & Dohme LLC
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Phase III 13 countries Daiichi Sankyo Inc.
A Phase 1b/2, Study of I-DXd in Combination with Atezolizumab with or without Carboplatin in First-line ES‑SCLC Recruiting

2023-509629-36-00 Phase I/II 2 countries Daiichi Sankyo Inc.
A clinical study of ifinatamab deruxtecan and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK-3475-06E) Recruiting

2024-514273-22-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
A clinical study of treatments for non-small cell lung cancer (MK-3475-01H) Recruiting

2024-518761-10-00 Phase II 6 countries Merck Sharp & Dohme LLC
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Phase I/II 7 countries Merck Sharp & Dohme LLC
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph… Recruiting

2023-509630-19-00 Phase III 11 countries Daiichi Sankyo Inc.
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting

2024-517423-40-00 Phase III 13 countries Merck Sharp & Dohme LLC
A clinical study of MK-6070 and ifinatamab deruxtecan in people with small cell lung cancer (MK-6070-002) Recruiting

2024-517926-25-00 Phase I/II 1 country Merck Sharp & Dohme LLC
Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting

2023-509632-26-00 Phase I/II 9 countries Daiichi Sankyo Inc.
I-DXd in Patients With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Ended

2024-512368-79-00 Phase II 3 countries Daiichi Sankyo Inc.

Showing 1–13 of 13 trials

← All drugs A–Z